Skip to main content
  • Saved

made a Post

Dual GIP and GLP‐1 Receptor Agonist, Tirzepatide, Improves Lipoprotein Biomarkers Associated with Insulin Resistance and Cardiovascular Risk in Patients with Type 2 Diabetes

Dual GIP and GLP‐1 Receptor Agonist, Tirzepatide, Improves Lipoprotein Biomarkers Associated with Insulin Resistance and Cardiovascular Risk in Patients with Type 2 Diabetes

Source :

https://dom-pubs.onlinelibrary.wiley.com/doi/abs/10.1111/dom.14174

Cookies are disabled for this browser. Wiley Online Library requires cookies for authentication and use of other site features; therefore, cookies must be enabled to browse the site. Detailed information on how Wiley uses cookies can be found in our Privacy Policy.